Meropenem-Vaborbactam as Salvage Therapy for Ceftazidime-Avibactam-, Cefiderocol-Resistant ST-512 Klebsiella pneumoniae-Producing KPC-31, a D179Y Variant of KPC-3

Giusy Tiseo; Marco Falcone; Alessandro Leonildi; Cesira Giordano; Simona Barnini; Gabriele Arcari; Alessandra Carattoli; Francesco Menichetti

doi:10.1093/ofid/ofab141

Meropenem-Vaborbactam as Salvage Therapy for Ceftazidime-Avibactam-, Cefiderocol-Resistant ST-512 Klebsiella pneumoniae-Producing KPC-31, a D179Y Variant of KPC-3

Open Forum Infect Dis. 2021 Mar 20;8(6):ofab141. doi: 10.1093/ofid/ofab141. eCollection 2021 Jun.

Authors

Giusy Tiseo¹, Marco Falcone¹, Alessandro Leonildi², Cesira Giordano², Simona Barnini², Gabriele Arcari³, Alessandra Carattoli³, Francesco Menichetti¹

Affiliations

¹ Infectious Diseases Clinic, Department of Clinical and Experimental Medicine, Azienda Universitaria Ospedaliera Pisana, University of Pisa, Pisa, Italy.
² Microbiology Unit, Azienda Universitaria Ospedaliera Pisana, Pisa, Italy.
³ Department of Molecular Medicine, "Sapienza" University of Rome, Rome, Italy.

Abstract

A 68-year-old man had recurrent bacteremia by Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae resistant to ceftazidime-avibactam and cefiderocol. The sequencing of a target region showed that it harbored a KPC-3 variant enzyme (D179Y; KPC-31), which confers resistance to ceftazidime-avibactam and restores meropenem susceptibility. The patient was successfully treated with meropenem-vaborbactam.

Keywords: KPC; KPC-3; Klebsiella pneumoniae; ceftazidime-avibactam resistant; meropenem-vaborbactam.

Publication types

Case Reports